MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet

rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

MMS will be attending OCT East Coast 2026 on May 12–13 in New Brunswick, New Jersey.If you’ll be there, connect with Mar...
05/08/2026

MMS will be attending OCT East Coast 2026 on May 12–13 in New Brunswick, New Jersey.

If you’ll be there, connect with Mark Bernath, Director of Business Development, and Tara Shumack, Project Manager, to discuss current challenges and priorities in clinical trial outsourcing.

Book a meeting: https://hubs.li/Q04fY_T50

FDA guidance on limiting crossover in oncology trials raises a fundamental tension, how do we protect the integrity of o...
05/08/2026

FDA guidance on limiting crossover in oncology trials raises a fundamental tension, how do we protect the integrity of overall survival data without discouraging patient participation?

In this blog, MMS’s Senior Vice President of Strategic Statistical Services, Aiden Flynn, explores the regulatory trade-offs and how statistical methods can help clarity and recruitment coexist.

Read the blog: https://hubs.li/Q04fXRLF0

05/06/2026

Sharon Morton, Principal Regulatory Strategist at MMS, shares her perspective on recent MHRA clinical trial reforms and how they are reshaping the UK regulatory landscape. She discusses what the changes mean in practice for sponsors, from faster, risk‑proportionate approvals and streamlined submissions to increased transparency and patient‑focused reporting, while maintaining a clear focus on safety and quality.

Get in touch to book a consultation with Sharon: https://hubs.li/Q04fDBHz0

We’re heading to OCT Europe 2026 tomorrow.MMS' Sal Siam, Director of Business Development, and Lucy Sutton, Vice Preside...
05/05/2026

We’re heading to OCT Europe 2026 tomorrow.

MMS' Sal Siam, Director of Business Development, and Lucy Sutton, Vice President of Account Management, will be attending the 16th Annual Outsourcing in Clinical Trials Europe on 6–7 May in Barcelona, joining clinical operations leaders for practical discussions on outsourcing, innovation, and trial delivery.

If you’re attending, book a meeting today: https://hubs.ly/Q04fnMz30

As AI adoption accelerates in pharma, the real challenge isn’t speed, it’s governance.This blog explores why human overs...
05/01/2026

As AI adoption accelerates in pharma, the real challenge isn’t speed, it’s governance.

This blog explores why human oversight remains essential, what “good” AI governance looks like in regulated environments, and how organizations can move forward responsibly without slowing innovation.

Read the full perspective: https://hubs.li/Q04f7cNY0

Tomorrow: Inside FDA REMS Decision‑Making: A Fireside Chat for SponsorsIn this live webinar, former FDA, REMS expert Som...
04/29/2026

Tomorrow: Inside FDA REMS Decision‑Making: A Fireside Chat for Sponsors

In this live webinar, former FDA, REMS expert Somya Dunn will share an agency‑level perspective on how REMS are evaluated, designed, and aligned with NDA strategy, plus common misconceptions that can introduce unnecessary regulatory risk.

Register now to join the conversation: https://hubs.li/Q04dx0s_0

We’re delighted to be a sponsor of MichBio Drug Discovery & Development Symposium on May 11 in Ann Arbor.Duane Robinson ...
04/28/2026

We’re delighted to be a sponsor of MichBio Drug Discovery & Development Symposium on May 11 in Ann Arbor.

Duane Robinson will attend, and Jessica Murdock and Jeffrey Wiese will present at 1:30pm with a practical end-to-end overview of Investigational New Drug (IND) applications. They’ll cover where INDs fit in drug development and how sponsors can plan, prepare, and manage them effectively.

Amanda Beaster will also participate in a panel discussion on emerging trends in clinical trials and regulation at 2:15pm.

Book a meeting to connect with the team: https://hubs.li/Q04dGRLZ0

What does regulatory acceleration really mean for psychedelic therapies?In her latest blog, MMS Founder & CEO Uma Sharma...
04/27/2026

What does regulatory acceleration really mean for psychedelic therapies?

In her latest blog, MMS Founder & CEO Uma Sharma reflects on the new regulatory measures regarding psychedelics and why faster review raises the bar on evidence, ex*****on, and durability. Having worked across multiple psychedelic therapy programs, Dr Sharma brings deep, hands-on expertise in this emerging field.

Read the blog to explore her perspective: https://hubs.li/Q04dwZkj0

Get in touch via info@mmsholdings.com if you’d like to discuss your own program with Dr Sharma.

04/24/2026

The FDA’s Bayesian Methods Guidance highlights how Bayesian approaches can help address feasibility challenges, particularly in rare disease trials.

Watch Jamie Inshaw's latest video to see how Bayesian strategies can support pragmatic regulatory pathways in rare disease settings.

Read our case study to see Bayesian extrapolation in action: https://hubs.ly/Q04d0KRN0

Early‑phase oncology trials demand high‑stakes decisions, often with limited and evolving data.In our new blog, we discu...
04/23/2026

Early‑phase oncology trials demand high‑stakes decisions, often with limited and evolving data.

In our new blog, we discuss expert insights from clinical development, regulatory science, and statistics on how structured evidence frameworks, upfront quantitative planning, and patient‑focused decision‑making can help teams navigate uncertainty with greater confidence.

Read the blog: https://hubs.li/Q04d1gGT0

We’re looking forward to OCT Europe 2026!Sal Siam and Lucy Sutton will be attending the 16th Annual Outsourcing in Clini...
04/22/2026

We’re looking forward to OCT Europe 2026!

Sal Siam and Lucy Sutton will be attending the 16th Annual Outsourcing in Clinical Trials East Coast on 6–7 May 2026. The event brings together clinical operations leaders to share practical insights on outsourcing, innovation, and trial delivery.

If you’re attending, we’d love to connect.

Learn more: https://hubs.ly/Q04cHBHG0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Share